https://clinicaltrials.gov/ct2/show/NCT03700320?type=Intr&cond=Migraine&lupd_s=02%2F22%2F2019&lupd_d=14
Condition : Episodic Migraine
Interventions : Drug: Atogepant 60 mg; Drug: Standard of Care (SOC) Migraine Prevention Medication
Sponsor : Allergan
Recruiting
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
NCT03700320
Tue, 09 Oct 2018 12:00:00 EDT
Last Update Posted: 03/08/19 12:00PM
